Company
Molecular Partners
- Biotech
- Founded:
- 2004
- Headquarters:
- Zurich-Schlieren, Switzerland
- Offices:
- Concord, MA · Cambridge
Description
Molecular Partners develops DARPin therapeutics, including Radio-DARPins and logic-gated Switch-DARPins, to target DLL3, FAP x CD40, and CD33 x CD123 x CD70 x CD3 in cancer and serious disease treatment.
Related
Novo NordiskNovo Nordisk develops treatments and support for serious chronic diseases by applying scientific expertise and understanding of people’s…
BioInvent InternationalBioInvent International discovers and develops antibody therapeutics for cancer treatment, using immunology, cancer biology, antibody…
Prevision MedicinePrevision Medicine tests living cancer and healthy cells from a patient biopsy against 100+ drugs and combinations using a patented ex vivo…
Faron PharmaceuticalsFaron Pharmaceuticals creates cancer treatments that use patients’ immune systems, with bexmarilimab, an anti-Clever-1 antibody and myeloid…
CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
NETRIS PharmaNETRIS Pharma develops therapeutics that target Netrin-1 to overcome resistance to oncology treatments, producing monoclonal antibodies…
Anacalypsis TherapeuticsAnacalypsis Therapeutics creates precision gene- and pathway-based therapeutic strategies, biomarkers, and genetically linked targets to…
BioArcticBioArctic develops therapeutics and related technologies for neurodegenerative disorders, focusing on disease-modifying treatments and…
SpliceBioSpliceBio builds protein splicing–based genetic medicines and develops therapeutics for diseases caused by mutations in large genes,…